{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:10:53Z","timestamp":1780956653458,"version":"3.54.1"},"reference-count":20,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n A notable proportion of patients with ankylosing spondylitis (ie, radiographic axial spondyloarthritis [r-axSpA]) experience either inadequate responses or intolerance to available therapies, highlighting the need for additional treatment options that offer sustained disease control.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of vunakizumab, a novel anti\u2013interleukin (IL) 17A monoclonal antibody, in r-axSpA.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized, double-blind, placebo-controlled, phase 2 to 3 clinical trial was conducted in 38 hospitals in China. A total of 548 adult patients (aged \u226518 years) with active r-axSpA were enrolled between June 9, 2021, and March 30, 2023. Data were analyzed from November 3, 2023, to January 14, 2024.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n In phase 2, patients were randomized 2:2:1 to receive a subcutaneous dose of vunakizumab, 120 mg, vunakizumab, 240 mg, or placebo; vunakizumab, 120 mg was determined to be the recommended dose after interim analysis. In phase 3, patients were randomized 2:1 to receive vunakizumab, 120 mg or placebo at weeks 0, 2, 4, 8, and 12; from week 16, all patients received vunakizumab, 120 mg every 4 weeks through week 32.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the proportion of patients with improvement of 20% or greater in Assessment of Spondyloarthritis International Society response criteria (ASAS20) at week 16. Secondary end points were ASAS20 at week 32, improvement of 40% or greater in ASAS response criteria (ASAS40) at weeks 16 and 32, improvement of 20% or greater in 5 of 6 ASAS domains (ASAS5\/6) at weeks 16 and 32, and changes from baseline at weeks 16 and 32 in Bath Ankylosing Spondylitis Disease Activity Index score, Bath Ankylosing Spondylitis Functional Index score, Bath Ankylosing Spondylitis Metrology Index score, 36-Item Short Form Survey score, and Ankylosing Spondylitis Quality of Life Questionnaire score.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n During the entire study, 548 patients were randomized (mean [SD] age, 33.0 [8.9] years; 440 [80.3%] male), including 294 receiving vunakizumab, 120 mg and 146 receiving placebo. At week 16, the ASAS20 response rate was significantly higher with vunakizumab, 120 mg vs placebo (193 [65.6%] vs 62 [42.5%], respectively; difference, 23.2% [95% CI, 11.8%-34.0%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001); the ASAS40 response rate also favored vunakizumab, 120 mg vs placebo (136 [46.3%] vs 35 [24.0%], respectively; difference, 22.3% [95% CI, 13.3%-31.3%];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Responses with vunakizumab were sustained through 32 weeks. During the placebo-controlled period, incidence of adverse events (246 [83.7%] vs 119 [81.5%]) were comparable in the vunakizumab, 120 mg and placebo groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of patients with r-axSpA, vunakizumab, 120 mg significantly improved signs and symptoms of r-axSpA at week 16 compared with placebo, with sustained efficacy through 32 weeks, and demonstrated a tolerable safety profile. These findings support vunakizumab, 120 mg as a new treatment option for active r-axSpA.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04840485<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.11632","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:30:20Z","timestamp":1778254220000},"page":"e2611632","source":"Crossref","is-referenced-by-count":1,"title":["Vunakizumab for Radiographic Axial Spondyloarthritis"],"prefix":"10.1001","volume":"9","author":[{"given":"Jian","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Chinese People\u2019s Liberation Army General Hospital, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhao","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cundong","family":"Mi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Affiliated Hospital of Guangxi Medical University, Nanning, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyun","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianwang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Guangdong Second Provincial General Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwang","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Second Affiliated Hospital of Nanchang University, Nanchang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The Affiliated Hospital of Nanjing University Medical School, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zhengzhou Central Hospital, Zhengzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Second Affiliated Hospital of Guangzhou, University of Chinese Medicine\u2013Guangdong Provincial Hospital of Chinese Medicine, Guangzhou"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasong","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zhejiang Provincial People\u2019s Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihui","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First Affiliated Hospital of Hainan Medical University, Hainan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Du","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Jinghua Municipal Central Hospital, Jinghua, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Shandong Provincial Hospital of Traditional Chinese Medicine, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqiang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First People\u2019s Hospital of Foshan, Foshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The First People\u2019s Hospital of Foshan, Foshan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical University, Bengbu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Hospital of Shanxi Medical University, Taiyuan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Jiujiang First People\u2019s Hospital, Jiujiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaxiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Shandong Provincial Hospital, Jinan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xue","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Zhongshan Hospital Xiamen University, Xiamen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexia","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Qinghai University Affiliated Hospital, Xining, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiankang","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Pingxiang People\u2019s Hospital, Pingxiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangli","family":"Dong","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals, Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Lin","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals, Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuna","family":"Du","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals, Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Bai","sequence":"additional","affiliation":[{"name":"Jiangsu Hengrui Pharmaceuticals, Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Chinese People\u2019s Liberation Army General Hospital, Beijing"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"issue":"1","key":"zoi260353r1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","article-title":"ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.","volume":"82","author":"Ramiro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"9570","key":"zoi260353r2","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0140-6736(07)60635-7","article-title":"Ankylosing spondylitis.","volume":"369","author":"Braun","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"zoi260353r3","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41584-022-00761-z","article-title":"Treatment of axial spondyloarthritis: an update.","volume":"18","author":"Danve","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"zoi260353r4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","article-title":"2019 Update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis.","volume":"71","author":"Ward","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"zoi260353r5","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies.","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"zoi260353r6","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17a inhibitor, in ankylosing spondylitis.","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"issue":"10163","key":"zoi260353r7","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"zoi260353r8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W).","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"zoi260353r9","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1136\/ard-2022-223595","article-title":"Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials.","volume":"82","author":"van der Heijde","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi260353r10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/ard-2023-224803","article-title":"Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies.","volume":"83","author":"Baraliakos","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"zoi260353r11","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1007\/s40265-024-02110-8","article-title":"Vunakizumab: first approval.","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"zoi260353r12","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17446","article-title":"Efficacy and safety of vunakizumab in moderate-to-severe chronic plaque psoriasis: a randomized, double-blind, placebo-controlled phase 3 trial.","author":"Yan","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"zoi260353r13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jaad.2022.01.005","article-title":"A multicenter, randomized, double-blinded, placebo-controlled, dose-ranging study evaluating the efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis.","volume":"87","author":"Zhang","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"20","key":"zoi260353r14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"24","key":"zoi260353r15","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1002\/sim.2389","article-title":"Testing and estimation in flexible group sequential designs with adaptive treatment selection.","volume":"24","author":"Posch","year":"2005","journal-title":"Stat Med"},{"issue":"21","key":"zoi260353r16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1097\/CM9.0000000000001099","article-title":"Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, phase III China-centric study, MEASURE 5.","volume":"133","author":"Huang","year":"2020","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"zoi260353r17","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1186\/s13075-017-1490-y","article-title":"Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.","volume":"19","author":"Pavelka","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"zoi260353r18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","article-title":"Secukinumab efficacy in anti-TNF\u2013naive and anti-TNF\u2013experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study.","volume":"76","author":"Sieper","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"zoi260353r19","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-018-0123-5","article-title":"Efficacy and safety of secukinumab 150 mg with and without loading regimen in ankylosing spondylitis: 104-week results from MEASURE 4 study.","volume":"5","author":"Kivitz","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"5","key":"zoi260353r20","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1136\/annrheumdis-2020-216980","article-title":"Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.","volume":"79","author":"van der Heijde","year":"2020","journal-title":"Ann Rheum Dis"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2848776\/zhu_2026_oi_260353_1777988997.76921.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:30:21Z","timestamp":1778254221000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2848776"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.11632","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]}}}